Nesfatin-1 and the cardiovascular system: central and pheripheral actions and cardioprotection

Current Drug Targets

Volumn 16, Issue 8, 2015, Pages 877-883

  Imbrogno, Sandra ^a   Angelone, Tommaso ^a   Cerra, Maria C ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Cardioprotection; Cardiovascular physiology; Neuropeptides

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BRAIN NATRIURETIC PEPTIDE; CALCIUM BINDING PROTEIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC GMP; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 4; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE RECEPTOR A; NESFATIN 1; NEUROPEPTIDE; NUCLEOBINDIN 2; PROTIRELIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; CARDIOTONIC AGENT; DNA BINDING PROTEIN; NERVE PROTEIN; NUCLEOBINDIN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR FUNCTION; ENERGY METABOLISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART PERFORMANCE; HEART PROTECTION; HEART RATE; HUMAN; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; INOTROPISM; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; ANIMAL; CARDIAC MUSCLE; GENETICS; ISCHEMIC POSTCONDITIONING; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM-BINDING PROTEINS; CARDIOTONIC AGENTS; DNA-BINDING PROTEINS; ENERGY METABOLISM; HUMANS; ISCHEMIC POSTCONDITIONING; MYOCARDIUM; NERVE TISSUE PROTEINS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION;

EID: 84940922495     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150408101431     Document Type: Article

References (50)

1. Angelone T, Quintieri AM, Amodio N, Cerra MC. Endocrine orchestration of cardiovascular, gastrointestinal and hypothalamic control. Curr Med Chem 2011; 18(32): 4976-86.
2. Vona-Davis LC, McFadden DW. NPY family of hormones: clinical relevance and potential use in gastrointestinal disease. Curr Top Med Chem 2007; 7(17): 1710-20.
3. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin- 1 as a satiety molecule in the hypothalamus. Nature 2006; 443(7112): 709-12.
4. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB. Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 2005; 493(1): 63- 71.
5. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150(1): 232-8.
6. Stengel A, Goebel M, Taché Y. Nesfatin-1: a novel inhibitory regulator of food intake and body weight Obes Rev 2011; 12: 261- 71.
7. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin- 1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391(1): 1039-42.
8. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28(12): 2372-81.
9. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150(1): 232-8.
10. Mimee A, Smith PM, Ferguson AV. Nesfatin-1 influences the excitability of neurons in the nucleus of the solitary tract and regulates cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2012; 302(11): R1297-304. doi: 10.1152/ajpregu.00266. 2011.
11. Angelone T, Filice E, Pasqua T, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci 2013; 70(3): 495-509. doi: 10.1007/s00018-012-1138-7.
12. Brailoiu GC, Dun SL, Brailoiu E, et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007; 148(10): 5088-94.
13. Pałasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 2012; 46(3): 105-12. doi: 10.1016/j.npep.2011.12.002
14. Miura K, Titani K, Kurosawa Y, Kanai Y. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem Biophys Res Commun 1992; 187: 375-80.
15. Barnikol-Watanabe S, Gross NA, Götz H, et al. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler 1994; 375: 497-512.
16. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150(2): 662-71.
17. Foo KS, Brismar H, Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008; 156: 563-79.
18. Goebel-Stengel M, Wang L, Stengel A, Taché Y. Localization of nesfatin-1 neurons in the mouse brain and functional implication. Brain Res 2011; 1396: 20-34.
19. Goebel-Stengel M, Wang L, Stengel A, Tache Y. Localization of nesfatin-1 neurons in mouse brain and functional implication. Brain Res 2009; 1396: 20-34.
20. Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Brain Res Rev 2004; 47: 126-44.
21. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004; 25: 150-76.
22. Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: An overview and future clinical application. Endocrine J. 2009; 56: 537-43.
23. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007; 28: 2223-28.
24. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28(12): 2372-81.
25. Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009; 381: 643-8.
26. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin- 1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 3169-80.
27. Garcia-Galiano D, Pineda R, Ilhan T, et al. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology 2012; 153: 1959-71.
28. Stengel A. Nesfatin-1: An Affair of the Heart. Endocrinology 2013; 154(12): 4443-5.
29. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of Nesfatin-1 are negatively correlated with body mass index in nonobese males. Clin Endocrinol (Oxf) 2010; 73: 484-90.
30. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin- 2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204: 255-63.
31. Feijóo-Bandín S, Rodríguez-Penas D, García-Rúa V, et al. Nesfatin- 1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4. Endocrinology 2013; 154(12): 4757- 67.
32. Kronebusch PJ, Singer SJ. The microtubule-organizing complex and the Golgi apparatus are co-localized around the entire nuclear envelope of interphase cardiac myocytes. J Cell Sci 1987; 88: 25- 34.
33. McFarland TP, Milstein ML, Cala SE. Rough endoplasmic reticulum to junctional sarcoplasmic reticulum trafficking of calsequestrin in adult cardiomyocytes. J Mol Cell Cardiol 2010; 49: 556-64.
34. Maejima Y, Sedbazar U, Suyama S, et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 2009; 10(5): 355-65.
35. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 2009; 297(2): R330- R336.
36. Brailoiu GC, Deliu E, Tica AA, et al. Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats. J Neurochem 2013; 126(6): 739-48.
37. Brailoiu GC, Dun SL, Brailoiu E, et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007; 148(10): 5088-94
38. Yosten GL, Redlinger L, Samson WK. Evidence for a role of endogenous nesfatin-1 in the control of water drinking. J Neuroendocrinol 2012; 24(7): 1078-84.
39. Fischmeister R, Méry PF. Regulation of cardiac calcium current by cGMP/NO route. C.R. Sci Soc Biol Philos 1996; 190: 181-206.
40. Cerra MC, Pellegrino D. Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 2007; 14(5): 585-99.
41. Penna C, Pasqua T, Perrelli MG, Pagliaro P, Cerra MC, Angelone T. Postconditioning with glucagon like peptide-2 reduces ischemia/ reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels. Basic Res Cardiol 2012; 107(4): 272. doi: 10.1007/s00395-012-0272-6.
42. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 2011; 14(5): 833-50.
43. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011; 14(5): 893-907.
44. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 9(2): 318-28.
45. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010; 105: 771-85
46. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98: 9050-55.
47. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-60.
48. Sims MW, Winter J, Brennan S, et al. PKC-mediated toxicity of elevated glucose concentration on cardiomyocyte function. Am J Physiol - Heart Circ Physiol 2014; 307(4): H587-H597 doi: 10.1152/ajpheart.00894.2013.
49. Apaijai N, Chattipakorn SC, Chattipakorn N. Roles of obeseinsulin resistance and anti-diabetic drugs on the heart with ischemia- reperfusion injury. Cardiovasc Drugs Ther 2014; 28(6): 549- 62.
50. Akhmedov AT, Rybin V, Marín-García J. Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. Heart Fail Rev 2015; 20(2): 227-49.